CAJ | 학술논문

干细胞%干细胞移植%脐带间充质干细胞%骨髓间充质干细胞%脊髓小脑性共济失调%运动障碍%腰穿%ICARS评分%异体脐带%细胞移植%脐血%免疫表型%老年痴呆%国家自然科学基金%干细胞图片文章榦細胞%榦細胞移植%臍帶間充質榦細胞%骨髓間充質榦細胞%脊髓小腦性共濟失調%運動障礙%腰穿%ICARS評分%異體臍帶%細胞移植%臍血%免疫錶型%老年癡呆%國傢自然科學基金%榦細胞圖片文章
간세포%간세포이식%제대간충질간세포%골수간충질간세포%척수소뇌성공제실조%운동장애%요천%ICARS평분%이체제대%세포이식%제혈%면역표형%노년치태%국가자연과학기금%간세포도편문장

　　背景：脊髓小脑性共济失调是临床上较常见的以进行性加重的四肢共济运动障碍为主要临床表现的中枢神经系统变性疾病，常规药物治疗效果欠佳。目的：观察自体骨髓间充质干细胞以及异体脐带间充质干细胞输注治疗脊髓小脑性共济失调的临床效果。方法：对接受间充质干细胞治疗的27例确诊脊髓小脑性共济失调患者进行综合统计分析，其中6例行自体骨髓间充质干细胞腰穿治疗，21例行异体脐带间充质干细胞腰穿结合静脉输注治疗，两组患者均采用世界神经病联合会国际合作共济失调量表(International Cooperative Ataxia Rating Scale，ICARS)对患者治疗前后神经功能进行评定。结果与结论：所有27例脊髓小脑共济失调患者行间充质干细胞治疗过程中以及治疗前后均未及明显不良反应。其中6例患者采用自体骨髓间充质干细胞治疗后效果均不明显，另外21例患者行异体脐带间充质干细胞输注治疗，治疗后3个月与治疗前比较，患者自觉症状均有一定程度改善，ICARS 评分明显降低(P <0.05)。说明脐带间充质干细胞治疗是安全的，可以一定程度地改善脊髓小脑性共济失调患者的临床症状，提高患者生活质量。
　　배경：척수소뇌성공제실조시림상상교상견적이진행성가중적사지공제운동장애위주요림상표현적중추신경계통변성질병，상규약물치료효과흠가。목적：관찰자체골수간충질간세포이급이체제대간충질간세포수주치료척수소뇌성공제실조적림상효과。방법：대접수간충질간세포치료적27례학진척수소뇌성공제실조환자진행종합통계분석，기중6례행자체골수간충질간세포요천치료，21례행이체제대간충질간세포요천결합정맥수주치료，량조환자균채용세계신경병연합회국제합작공제실조량표(International Cooperative Ataxia Rating Scale，ICARS)대환자치료전후신경공능진행평정。결과여결론：소유27례척수소뇌공제실조환자행간충질간세포치료과정중이급치료전후균미급명현불량반응。기중6례환자채용자체골수간충질간세포치료후효과균불명현，령외21례환자행이체제대간충질간세포수주치료，치료후3개월여치료전비교，환자자각증상균유일정정도개선，ICARS 평분명현강저(P <0.05)。설명제대간충질간세포치료시안전적，가이일정정도지개선척수소뇌성공제실조환자적림상증상，제고환자생활질량。
BACKGROUND: Spinocerebel ar ataxia is a common neurodegenerative disease characterized by slowly progressive movement incoordination of the limbs. It responds badly to common medication. OBJECTIVE: To observe the clinical effect of autologous bone marrow mesenchymal stem cells and al ogeneic umbilical cord mesenchymal stem cells tranfusion in the treatment of spinocerebel ar ataxia. METHODS: A total of 27 spinocerebel ar ataxia patients treated with mesenchymal stem cells treatment were included for comprehensive statistical analysis. Among these patients, six patients received autologous bone marrow mesenchymal stem cells lumbar puncture treatment and 21 patients received al ogeneic umbilical cord mesenchymal stem cells lumbar puncture treatment combined with intravenous infusion. The neurologic function of the patients in the two groups was evaluated with International Cooperative Ataxia Rating Scale before and after treatment. RESULTS AND CONCLUSION: There was no obvious adverse effect in the 27 spinocerebel ar ataxia patients during, before or after mesenchymal stem cells treatment. The effect of autologous bone marrow mesenchymal stem cells in six patents was not significant; for the other 21 patients treated with al ogeneic umbilical cord mesenchymal stem cells transfusion, the subjective symptoms of the patients were improved, and the International Cooperative Ataxia Rating Scale scores were decreased significantly at 3 months after treatment when compared with those before treatment (P < 0.05). The results suggest that umbilical cord mesenchymal stem cells treatment is safe and able to ameliorate the clinical symptoms and improve life quality of spinocerebel ar ataxia patients to some extent.